About Jade Therapeutics
Jade Therapeutics is a Healthcare company based in Salt Lake City (United States) founded in 2012, and was acquired by EyeGate in March 2016. It operates as a polymer-based products for ophthalmic drug delivery are developed using iontophoresis. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified. Its legal entity is Jade Therapeutics, Inc. Its competitors include Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope and 5 more; 8 of its 10 listed competitors have raised funding.
Company details
Jade Therapeutics was founded in 2012 in Salt Lake City, United States, within the biotechnology sector. Locally administered polymer-based systems for treating ophthalmic conditions are developed, with transscleral iontophoresis employed to target drugs in anterior and posterior eye segments. An exclusive worldwide license to BioTime, Inc.s thiolated, cross-linked hyaluronic acid platform for ocular delivery was secured. The company was acquired by EyeGate Pharma in 2016.
- Headquarters Salt Lake City, United States
- Stage Acquired
- SectorsHealthcare
- Website jadetherapeutics.com
- Social LinkedIn
- Acquired by EyeGate (Mar 2016)
- Legal Name Jade Therapeutics, Inc.
Funding Insights of Jade Therapeutics
- Total Rounds 3
- Last Round Grant — $725,000
- First Round $150,000
(Jun 2013)
- Investors Count 1
All 3 funding rounds of Jade Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2014 | $725,000 | Grant | – | – | |
| Jul 2013 | $153,642 | Grant | – | – | |
| Jun 2013 | $150,000 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Jade Therapeutics
Jade Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include EyeGate and National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
Therapeutics and drug delivery systems for eye diseases are developed. | 1998 | eyegatepharma.com | Waltham, United States |
Investor details for Jade Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Jade Therapeutics
4 dated milestones of Jade Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Jade Therapeutics is founded.
- Funding First funding round of $150K.
- Funding Latest funding round, Grant, of $725K.
- Exit Acquired by EyeGate.
Competitors of Jade Therapeutics
Jade Therapeutics has 10 listed competitors in our database, 8 of them funded. They include Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. | |
| nicox.com | 1996 | Valbonne, France | $271.01M | – | Nitric oxide-based therapeutics for glaucoma and eye conditions are developed. | |
| gyroscope.cc | 2016 | San Francisco, United States | – | – | Mobile SDK developed for app engagement and monetization strategies. | |
| meiragtx.com | 2015 | New York, United States | – | 358 | Gene therapies for ocular and neurodegenerative diseases are developed. | |
| perceivebio.com | 2021 | San Francisco, United States | $78M | – | Developer of therapeutics to treat diabetes and eye diseases | |
| alimerasciences.com | 2003 | Alpharetta, United States | $66.8M | 79 | Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | |
| oculis.com | 2003 | Pully, Switzerland | $93.21M | 2 | Ophthalmic drug design and delivery platforms are developed by Oculis. | |
| gensight-biologics.com | 2011 | Paris, France | $76.63M | – | Viral vector-based gene therapies for retinal diseases are developed. |
Detailed competitors of Jade Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
10 companies that operate in the same segment as Jade Therapeutics (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Jade Therapeutics
Complete news archive for Jade Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jade Therapeutics
Jade Therapeutics was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Jade Therapeutics is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Jade Therapeutics was founded in 2012 in Salt Lake City, United States, within the biotechnology sector. Locally administered polymer-based systems for treating ophthalmic conditions are developed, with transscleral iontophoresis employed to target drugs in anterior and posterior eye segments. An exclusive worldwide license to BioTime, Inc.s thiolated, cross-linked hyaluronic acid platform for ocular delivery was secured. The company was acquired by EyeGate Pharma in 2016.
Jade Therapeutics's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Jade Therapeutics has 2 investors. Key investors include EyeGate, and National Science Foundation.
Jade Therapeutics operates through Jade Therapeutics, Inc..
Yes. Jade Therapeutics was acquired by EyeGate in March 2016.